SREBF1 and cancer: Memorial Sloan Kettering Cancer Center has made the initial discovery that cancer cells harboring mutations in the PI3K-AKT signaling pathway have been shown to develop resistance to ferroptosis, attributed to the upregulation of the SREBP1/SCD protein complex, which governs fatty acid synthesis 37.